Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
F7	2155	CHEMBL204997	CHEMBL204997		DrugBank	10592235
F7	2155	CHEMBL377956	CHEMBL377956		DrugBank	10592235
F7	2155	NONACOG ALFA	CHEMBL2109205	ligand	DrugBank	10617609, 10498586, 10381508, 10938981, 659613, 10192655
F7	2155	MENADIONE	CHEMBL590	activator	DrugBank	17139284, 17016423
F7	2155	CHEMBL206387	CHEMBL206387	inhibitor	GuideToPharmacologyInteractions
F7	2155	CHEMBL209022	CHEMBL209022		DrugBank	10592235

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
F7	rs510317	GG	phenprocoumon	"dosage","metabolism/PK"	yes	Daily dose of phenprocoumon is not significantly associated with this SNP. Daily dose is negatively correlated with age. This study published an algorithm for daily dose that includes height, although height was not significant in univariate analysis. This SNP is also not significantly associated with phenprocoumon concentration.	Genotype GG is not associated with increased dose of phenprocoumon as compared to genotypes AA + AG.	21110013	982046680
F7	rs6046	A	warfarin	dosage	no		Allele A is not associated with dose of warfarin as compared to allele G.	28049362	1449251734
F7	rs510317	AA + AG	warfarin	dosage	yes	using the extreme-discordant-phenotype (EDP) methodology. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram.	Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.	19387626	982036914
F7	rs510335	GG	phenprocoumon	"dosage","efficacy"	no	This study was done in two phases. The first was the initiation phase, defined as the time to reach an INR in the therapeutic range as measured twice in series. The second was the maintenance phase, which began immediately after the initiation phase, and lasted for 91 days. It is of note that not all patients were included in each phase of study. No association was seen between this SNP and any outcome in either the initiation phase or the maintenance phase.	Genotype GG is not associated with response to phenprocoumon as compared to genotypes GT + TT.	21057703	1043858523
F7	rs510335	GG	phenprocoumon	"dosage","metabolism/PK"	yes	Daily dose of phenprocoumon is not significantly associated with this SNP. Daily dose is negatively correlated with age. This study published an algorithm for daily dose that includes height, although height was not significant in univariate analysis. This SNP is also not significantly associated with phenprocoumon concentration.	Genotype GG is not associated with increased dose of phenprocoumon as compared to genotypes GT + TT.	21110013	982046684
F7	rs510317	AA	phenprocoumon	"dosage","efficacy"	no	This study was done in two phases. The first was the initiation phase, defined as the time to reach an INR in the therapeutic range as measured twice in series. The second was the maintenance phase, which began immediately after the initiation phase, and lasted for 91 days. It is of note that not all patients were included in each phase of study. No association was seen between this SNP and any outcome in either the initiation phase or the maintenance phase.	Genotype AA is not associated with response to phenprocoumon as compared to genotypes AG + GG.	21057703	1043858518